New Orleans - Calcium hydroxylapatite is similar to other dermal fillers in terms of efficacy and ease of administration, but less of it is necessary to get the job done, according to a Stanford University-based retrospective, prospective study. The study was performed by Hayes B. Gladstone, M.D., director, dermatologic surgery, Stanford University, Palo Alto, Calif., in conjunction with Mountain View, Calif., private practice dermatologic surgeon Greg S. Morganroth, M.D.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.